Telehealth Unit Economics
How Hims, Hers, and Ro Built Subscription Men's-Health Businesses
Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Not a drug; platforms prescribe FDA-approved and compounded products
Reference only. Not medical advice.
What can go wrong
The model's incentives push toward prescribing and retention rather than discontinuation. Critics note the prescriber-also-seller conflict and that asynchronous (no live visit) prescribing can under-screen for contraindications such as nitrate use with PDE5 inhibitors. Subscription auto-renewal and cancellation friction have drawn consumer complaints across the DTC telehealth category.
This is something to take to a clinician. The Atlas can tell you what is known about telehealth unit economics in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Hims & Hers Health (NYSE: HIMS) and Ro (Roman Health Ventures) built cash-pay, direct-to-consumer subscription businesses on the back of low-cost generic men's-health drugs. The model sources commodity generic active ingredients (sildenafil for ED, minoxidil/finasteride for hair) at pennies per dose, then bundles them with a paid telehealth consultation and a recurring monthly subscription. ED was the deliberate beachhead: discreet, high-demand, and a low-friction way to prove the D2C model and acquire patients who could later be cross-sold weight-loss, hair, mental-health, and hormone products.
Generic sildenafil as the wedge; subscriptions as the business.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
How it works
The economic engine is the spread between the commodity cost of a generic API and the subscription price the consumer pays. Generic sildenafil costs the platform a tiny fraction of the retail subscription, so the gross margin resembles software once the consultation and fulfillment layer is built. The key metric is the relationship between customer-acquisition cost (CAC), driven up by heavy paid advertising, and lifetime value (LTV), which depends on subscriber retention and successful cross-selling into higher-priced categories. Hims & Hers reports gross margins historically in the high-70s to low-80s percent range, more typical of a software company than a pharmacy.
The Catch: The Consult Is the Funnel
The 'free' or low-cost online consultation is not a charity; it is a customer-acquisition and prescribing funnel. The platform's revenue depends on the consultation converting to a recurring prescription, which structurally aligns the prescriber's employer with selling product. The cheap generic is the hook; the subscription and the cross-sell are the business.
What people get wrong
Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.
Who profits, and who pushes back
Margin-durability skeptics
Question whether software-like gross margins survive a shift from cheap generics toward branded GLP-1s, which carry far higher cost of goods and thinner unit economics.
Compounding-risk critics
Point out that revenue tied to compounded GLP-1s is exposed to FDA shortage-list changes and litigation, as seen when branded manufacturers pushed back and compounding access narrowed.
CAC/LTV skeptics
Argue that heavy paid-advertising spend keeps acquisition costs high and that the model depends on retention and cross-sell that may not hold as competition intensifies.
Platforms (Hims & Hers, Ro), their affiliated/partner pharmacies, the prescribing clinicians paid per consult, and the digital-ad ecosystem (Meta, Google) that captures a large share of CAC.
Set against the alternatives
Versus a traditional pharmacy, these platforms capture the spread between commodity generic cost and a recurring subscription price, yielding gross margins closer to software than to dispensing. Versus each other, Hims & Hers leaned into low-cost (including compounded) products and broad cross-sell and reached full-year GAAP profitability, Ro differentiates on insurance navigation and branded-drug concierge service, and LifeMD pairs telehealth with manufacturer partnerships at smaller scale. The shared vulnerability is that GLP-1 demand is migrating the revenue mix toward higher-cost branded drugs and manufacturer-controlled supply, compressing the generic-driven margin advantage that defined the original ED beachhead model.
| Company | Core model | Revenue driver | Note |
|---|---|---|---|
| Hims & Hers | DTC subscription | Generics + GLP-1 | GAAP-profitable; public (HIMS) |
| Ro | DTC + insurance nav | Branded GLP-1, ED, TRT | Private; concierge focus |
| LifeMD | DTC + manufacturer deals | Branded GLP-1, primary care | Public; smaller scale |
| Generic-ED beachhead | Cash-pay, recurring | Cross-sell into new lines | Low API cost, high margin |
Both companies avoid insurance and price for cash-pay consumers, which lets them set prices well above wholesale generic cost. Ro raised over $1 billion across rounds (General Catalyst, FirstMark, TQ Ventures) and reached a roughly $7 billion peak valuation; Hims & Hers went public via SPAC in 2021 and turned its first full-year GAAP profit in 2024. The category's defining tension is sustaining LTV as paid-acquisition costs rise and as flagship growth drivers (compounded GLP-1) face regulatory rollback.
What we do not know
- Can LTV hold as paid-acquisition costs climb and compounded-GLP-1 revenue is curtailed?
- How durable is retention once a customer's acute need (ED, hair) is met?
What could change
Manufacturer tie-upsDirect deals (e.g. Novo Nordisk) to sell branded GLP-1s shift supply control to drugmakers.Compounding restrictionsTightening of FDA shortage/bulks lists curtails compounded GLP-1 revenue.Margin mix shiftMove from pennies-per-dose generics toward branded drugs pressures the software-like margin profile.Category expansionCross-sell into longevity, hormones, and chronic-care subscriptions to lift lifetime value.
At a glance
- HIMS 2024 revenue
- $1.5 billion (up ~69% YoY)
- HIMS 2024 subscribers
- ~2.2 million
- HIMS 2024 net income
- ~$126 million (first full-year GAAP profit)
- Ro peak valuation
- ~$7 billion (Feb 2022 round)
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Telehealth Unit Economics. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- Children and teenagers. We have not checked what is known about younger people.
Sources
No sources recorded for this entry yet. Nothing on this page can be checked against a citation until that changes, so treat it as a summary awaiting its evidence.